EpimAb Biotherapeutics Inc.’s HKEX IPO Application Lapsed, Dual Antibody Pipeline Centered on EGFR/cMET
NewTimeSpace News: The Main Board listing application filed by EpimAb Biotherapeutics Inc. with the Stock Exchange of Hong Kong Limited on 18 December 2025 has lapsed after the six-month statutory validity period expired, with CITIC Securities and China Merchants Bank International acting as the original joint sponsors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- XINTE ENERGY (01799.HK): Nan Xinjian Resigns as General Manager and Executive Director; Wang Bin Appointed General Manager and Proposed as Executive Director
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
- SCIENTECH (02291.HK): Acquires 54.2384% Equity of Shanghai Minwei Biotechnology for RMB 1.088 Billion, Constituting Major and Connected Transaction
